 |
|
|
|
 |
|
|
| Article 1 to 10 out of 18 concerning NicOx S.A.
|
-
NicOx announces departure of Damian Marron for CEO position
(05/29/2008)
NicOx S.A. announced that Damian Marron, Executive Vice President of Corporate Development, will be leaving the company on 30th May to become Chief Executive Officer of an early clinical stage biopharmaceutical company. Damian's responsibilities ...
-
NicOx announces initiation of first phase 1 study of investigational nitric oxide-donating agent in hypertensive patients
(05/14/2008)
NicOx S.A. announced that Merck & Co., Inc. has initiated the first in a series of planned clinical studies, in mild to moderate hypertensive patients, under the companies' collaborative agreement to develop new nitric oxide-donating antihypertensive...
-
NicOx announces U.S. phase 2a results for PF-03187207 and gives an update on continuing NO-prostaglandin program
(05/07/2008)
NicOx S.A. announced the results of a U.S. phase 2 study, conducted by its partner Pfizer Inc, which compared the safety and efficacy of various doses of PF-03187207 to Xalatan® (latanoprost) 0.005% in patients with primary open-angle glaucoma and ...
-
NicOx signs agreement for the commercial manufacture of naproxcinod drug substance
(03/20/2008)
NicOx S.A. announced it has signed an agreement with the fine chemical company Archimica, for the commercial manufacturing and supply of naproxcinod drug substance (or active pharmaceutical ingredient, API). Naproxcinod is NicOx' lead ...
-
NicOx initiates two large ABPM studies for naproxcinod in hypertensive patients with osteoarthritis
(03/05/2008)
NicOx S.A. announced the initiation of two large clinical pharmacology studies in the United States, which will assess the blood pressure profile of naproxcinod in comparison to ibuprofen and naproxen, using the Ambulatory Blood Pressure Monitoring ...
-
NicOx signs extension of ophthalmology agreement with Pfizer
(01/09/2008)
NicOx S.A. announced it has signed an extension of its March 2006 collaboration agreement, which grants Pfizer Inc the exclusive right to apply its proprietary nitric oxide-donating technology to drug discovery research in the field of ...
-
NicOx completes enrolment in second pivotal phase 3 study for naproxcinod and provides development update
(12/17/2007)
NicOx S.A. announced it has successfully completed the enrolment of 1020 patients in the 302 pivotal phase 3 study for naproxcinod, in-line with projections. Naproxcinod is the Company's lead investigational drug product and the first compound in ...
-
NicOx' presents naproxcinod ABPM data
(11/08/2007)
NicOx S.A. announced that clinical results of an exploratory pharmacodynamic study for naproxcinod using Ambulatory Blood Pressure Monitoring (ABPM) were presented at the American Heart Association Scientific Sessions 2007, in Orlando, Florida. ...
-
NicOx opens US headquarters in New Jersey
(10/16/2007)
NicOx S.A. announced the opening of its United States headquarters in Warren, New Jersey, where the Company will base its Commercial Affairs and U.S. Clinical Operations departments. Mr. Sanjiv Sharma, who was appointed last April as Vice President ...
-
NicOx reports Topigen to advance TPI-1020 into phase 2 for COPD following promising clinical results
(09/12/2007)
NicOx S.A. reported that Topigen Pharmaceuticals Inc. has disclosed promising top-line results from its first phase 2 clinical study for TPI-1020, a new chemical entity licensed from NicOx which is a novel respiratory anti-inflammatory. These ...
Additional information
NicOx S.A.
Sophia Antipolis, France
Company
|
|
|
|
|
|
Top
